Producción científica2026· Journal of Functional Biomaterials
Marginal Bone Remodeling and Peri-Implant Inflammatory Biomarkers Around Crestally Placed Tissue-Level and Subcrestally Placed Bone-Level Implants: A Prospective Randomized Study
AutoresMarkel Diéguez-Pereira, David Chávarri-Prado, Oier Montalban-Vadillo, Rodrigo Cabezón-Palacios, Alejandro Estrada-Martínez, Miguel Beltrán-Guijarro, Esteban Pérez-Pevida
Por qué importa
¿Importa colocar un implante a nivel de tejido en la cresta o uno a nivel óseo 2 mm por debajo de ella? Este ensayo clínico aleatorizado y prospectivo comparó ambas opciones en 42 implantes de 23 pacientes, restaurados con un pilar transepitelial definitivo colocado una sola vez. Tras una media de casi 20 meses de carga, los implantes a nivel óseo subcrestales perdieron algo menos hueso marginal (0,29 frente a 0,55 mm), pero la diferencia no fue estadísticamente significativa y su relevancia clínica es limitada. Los marcadores inflamatorios del fluido periimplantario (IL-1β y MMP-8) tampoco mostraron diferencias. Los autores advierten que, al variar varios factores a la vez, el resultado no puede atribuirse solo al diseño del implante.
(1) Background: Long-term dental implant performance depends on the interaction between mechanical load distribution and peri-implant tissue response. The influence of implant configuration and vertical placement on marginal bone remodeling and early inflammatory signaling remains unclear. Therefore, the aim of this study was to compare crestally placed tissue-level (TL) and subcrestally placed bone-level (BL) implant configurations regarding marginal bone loss (MBL) and inflammatory biomarkers in the peri-implant crevicular fluid (PICF). (2) Methods: In this prospective randomized trial, 58 implants (29 TL, 29 BL) randomly allocated at the implant level were placed in 30 healthy patients; 42 implants (21 TL, 21 BL) in 23 patients were analysed. TL implants were placed at the crestal level, whereas BL implants were positioned 2 mm subcrestally and restored after 2 months using definitive transepithelial abutments (one-time abutment concept). MBL was assessed radiographically at prosthesis delivery, 6 months after loading and at the final follow-up (12–24 months after loading; mean 19.9 months). PICF was collected 6 months after loading to determine interleukin-1β (IL-1β) and matrix metalloproteinase-8 (MMP-8) levels by enzyme-linked immunosorbent assay (ELISA). Data were analysed with linear mixed-effects models accounting for clustering of implants within patients and for repeated measurements. (3) Results: At the final follow-up, mean MBL was 0.55 mm for TL and 0.29 mm for BL implants; the between-group difference in change (0.26 mm; 95% CI −0.01 to 0.53 mm) was not statistically significant (p = 0.058). No statistically significant differences were detected in IL-1β (p = 0.723) or MMP-8 (p = 0.777) concentrations, and neither biomarker was significantly associated with bone loss after adjustment. (4) Conclusions: Subcrestally placed BL implants restored with a one-abutment–one-time protocol showed numerically, but not significantly, smaller marginal bone loss than crestally placed TL implants, and the magnitude of the difference was of limited clinical relevance. Because the configurations differed in several respects, the results cannot be attributed to implant design alone.
Diéguez-Pereira M, Chávarri-Prado D, Montalban-Vadillo O, Cabezón-Palacios R, Estrada-Martínez A, Beltrán-Guijarro M, et al. Marginal Bone Remodeling and Peri-Implant Inflammatory Biomarkers Around Crestally Placed Tissue-Level and Subcrestally Placed Bone-Level Implants: A Prospective Randomized Study. Journal of Functional Biomaterials. 2026. doi:10.3390/jfb17110556